<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01845675</url>
  </required_header>
  <id_info>
    <org_study_id>TEPNET</org_study_id>
    <nct_id>NCT01845675</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor</brief_title>
  <official_title>Temozolomide or Dacarbazine-based Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in
      well-differentiated pancreatic neuroendocrine tumor
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicities</measure>
    <time_frame>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Advanced Well-differentiated Pancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>temozolomide or dacarbazine-based chemotherapy, endostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endostatin 15mg/d，IV infusion, d1-d14 Temozolomide 150-200mg/m2/d，p.o., d1-d7 or dacarbazine 250mg/m2/d, IV infusion, d1-5, 5-FU 500mg/m2/d, IV infusion d1-5 Repeat every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide or dacarbazine-based chemotherapy, endostatin</intervention_name>
    <arm_group_label>temozolomide or dacarbazine-based chemotherapy, endostatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age and older

          2. ECOG ≤2

          3. Pathologically confirmed locally advanced or metastatic well-differentiated pancreatic
             neuroendocrine tumor.

          4. Prior treatment with one-line chemotherapy is allowed, with the exception of prior
             treatment with temozolomide or dacarbazine or endostatin within the past 6 months

          5. Disease progressed during or after last therapy

          6. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of
             all prior systemic anticancer therapy

          7. Disease progressed within the past 12 months。

          8. Patients must have at least one measurable site of disease according to RECIST1.1
             criteria that has not been previously irradiated.

          9. Adequate bone marrow, liver and renal function

         10. Life expectancy 3 months or more

         11. Patient informed consent。

        Exclusion Criteria:

          1. Concurrent use of Octreotide or other drug that may have efficacy in neuroendocrine
             tumor.

          2. 2 or more lines of prior chemotherapy。

          3. Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study

          4. Uncontrolled infectious disease。

          5. Other malignancies within the past 5 years except for adequately treated carcinoma of
             the cervix or basal or squamous cell carcinoma of the skin

          6. Uncontrolled brain or leptomeningeal metastases

          7. Patients with known hypersensitivity to temozolomide or endostatin。

          8. Patient could not take tablets。
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Medical Oncology, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>YueJuan Cheng</investigator_full_name>
    <investigator_title>attending medical oncologist</investigator_title>
  </responsible_party>
  <keyword>temozolomide</keyword>
  <keyword>endostatin</keyword>
  <keyword>advanced</keyword>
  <keyword>well-differentiated</keyword>
  <keyword>pancreatic neuroendocrine tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

